Hair Loss Drug Finasteride Under Scrutiny for Psychiatric Risks

A medication taken by millions of people worldwide for hair loss is facing renewed scrutiny over its potential psychiatric effects. Finasteride, commonly prescribed to treat male pattern baldness, has been connected to depression and suicide in a new review that questions why regulatory agencies have not acted more decisively on the evidence.

Professor Mayer Brezis has published a comprehensive analysis examining global data on finasteride's psychiatric risks. His findings point to a troubling pattern: evidence of harm has existed for years, yet both the pharmaceutical company Merck and regulatory bodies like the FDA have been slow to respond. The review raises fundamental questions about how we balance cosmetic treatments against serious mental health risks.

The Evidence Behind the Concerns

Finasteride works by blocking an enzyme that converts testosterone into dihydrotestosterone, a hormone linked to hair loss. But this mechanism also affects brain chemistry in ways that researchers are still working to understand. The drug's impact on neurosteroids, chemicals that help regulate mood and emotional responses, may explain why some people experience psychiatric symptoms while taking it.

The review compiled data from multiple countries showing patterns of depression and suicidal thoughts among finasteride users. These aren't isolated incidents or anecdotal reports. The evidence comes from post-marketing surveillance, medical databases, and case studies that have accumulated over the years since the drug was approved for cosmetic use.

*Photo: Atahan Demir · Pexels*

What makes this situation particularly striking is that finasteride is often used for a cosmetic concern rather than a life-threatening condition. Unlike medications that treat serious illnesses, where side effects might be an acceptable trade-off, hair loss treatments occupy different ethical territory. The calculation of risk versus benefit changes when the condition being treated doesn't threaten physical health.

Why Warnings Were Ignored

Professor Brezis's analysis doesn't just document the psychiatric risks. It examines why regulatory action has been so limited despite the evidence. The pattern he describes is one of inaction, where signals of harm were either dismissed or not investigated thoroughly enough to prompt meaningful change.

The pharmaceutical company Merck has faced criticism for its handling of safety data. Regulatory agencies, which rely partly on company-reported information, also appear to have been slow to demand more rigorous post-marketing studies. These are the kinds of investigations that follow a drug after approval, tracking real-world effects across large populations over time.

The review calls for urgent regulatory reforms. Brezis argues that the current system failed to protect public health in this case, and that stronger mechanisms are needed to ensure psychiatric side effects are taken seriously. This is especially important for drugs used cosmetically, where the threshold for acceptable risk should arguably be lower.

*Photo: qmicertification design · Pexels*

What This Means for Informed Consent

One of the core issues this review raises is informed consent. When someone considers taking finasteride for hair loss, do they truly understand the potential psychiatric risks? Are doctors adequately informed so they can have meaningful conversations with patients about what to watch for?

The evidence suggests that many people may not have received complete information. Warning labels have been updated in some countries, but the process has been gradual and inconsistent. Some regulatory bodies have been more proactive than others, creating a patchwork of protections that depends on where someone lives.

For anyone currently taking finasteride or considering it, this review serves as a reminder to have open conversations with healthcare providers. Understanding both the benefits and the risks, particularly those affecting mental wellbeing, is essential for making decisions that align with personal values and health priorities.

A Call for Better Systems

Professor Brezis's work is ultimately a call for systemic change. He advocates for post-marketing studies that would provide clearer data about how finasteride affects different populations over time. He also pushes for regulatory processes that respond more quickly when signals of psychiatric harm emerge, rather than waiting for evidence to become overwhelming.

This isn't about banning a medication outright. It's about creating systems that prioritise transparency, rigorous ongoing research, and patient safety above all else. When a drug's effects on the brain can be this serious, the responsibility to monitor and inform becomes even more critical.

The story of finasteride and its psychiatric risks matters because it reveals gaps in how we oversee medications after they reach the market. It shows how cosmetic concerns can sometimes obscure serious health considerations, and how the voices raising alarms can go unheard for too long.

For anyone affected by the mental health effects of any medication, support is available through healthcare providers and mental health services.

ScienceDaily